EBV-induced post transplantation lymphoproliferative disorder (EBV-PTLD) is a life-threatening complication after allogeneic hematopoietic cell transplantation. Profound T-cell depletion of the allograft represents a major risk factor for EBV-PTLD. With regard to the increasing use of alternative stem cell sources such as cord blood or purified haploidentical stem cell grafts both associated with impaired immune reconstitution, the frequent occurrence of EBV-PTLD demands particular vigilance on laboratory changes and early symptoms. Here we have summarized today's knowledge about EBV-PTLD in a comprehensive review explaining the underlying mechanisms of EBV-based transformation, EBV-PTLD development, clinical presentation, incidence, diagnosis, screening, therapy and prognosis. In this context, we emphasize on the necessity of regularly applied screening tools and pre-emptive treatment strategies including anti-CD20 Abs particularly in high-risk patients to avoid disease progression to malignant lymphoma. Although EBV-PTLD has always been associated with a high mortality rate, novel immunotherapeutic approaches such as the transfer of EBV-specific T cells nowadays offer improved chances of disease control even at late stages.
INTRODUCTION
The term post transplant lymphoproliferative disorder (PTLD) generally refers to an EBV-driven B-cell proliferation occurring after a solid organ or allogeneic blood hematopoietic cell transplantation (HCT). This first stage may finally lead to the development of monoclonal B-cell neoplasias. The basic underlying mechanism clearly refers to the inability of the newly transferred donor immune system to control latently EBV-infected B cells of the host. Therefore, EBV-driven proliferation of B cells can certainly be anticipated in all kinds of severe immune suppression. However, the situation after allogeneic HCT creates a unique environment where EBV-infected B cells may have been depleted together with their immunological counterparts such as EBV-specific T cells. This opens opportunities for donor-derived EBV-infected B cells populating the severely immunocompromised host serving as an additional origin of EBV-PTLD after HCT and providing a timely delay of EBV-PTLD development. 1 The occurrence of EBV-PTLD after cord blood transplantation where the donor has unlikely been infected with EBV in the first place, however, represents an example of clearly host-derived EBV-PTLD. 2, 3 Published experience regarding the incidence of EBV-PTLD after allogeneic HCT ranges between 0.5 and 17% and is mainly based on single-centre experiences or retrospective studies limited by small numbers and diverse patient characteristics. [4] [5] [6] [7] However, Landgren et al. 8 collected data on 127 EBV-PTLD cases from 271 centres and found an elevated risk for developing PTLD especially in the first year after HCT (83%) with the highest occurrence during the first 6 months. However, late EBV-PTLD could be observed even up to 10 years after HCT. In a multivariate analysis, several risk factors were defined such as T-cell-depleting conditioning regimens, the use of anti-thymocyte globulin, acute and chronic GVHD, second allogeneic HCT and patient's age above 50 years. In patients with more than three risk factors, the overall incidence added up to 8.1% (Table 1 ). The presence of rising EBV copy numbers in the peripheral blood of HCT recipients was reported to be associated with the manifestation of EBV-PTLD later on, particularly when having failed to initiate pre-emptive treatment immediately. 9, 10 Whether serological determination of previous EBV encounters in donor and recipient is of predictive value for later EBV-PTLD development is not yet clear. Nevertheless, the presence of an EBV sero-mismatch between donor and recipient has been described to increase the risk of EBV-PTLD after HCT. 11 The role of assessing pre-transplant EBV early-Ag IgG levels may identify a further risk group. 12 Factors that have been controversially discussed are the use of anti-CD52 Ab (alemtuzumab) in the conditioning regimens, splenectomized patients or conditioning regimens containing TBI. 11, 13, 14 Interestingly, no significant influence of the underlying disease for EBV-PTLD development was found 13 leaving the longterm immunocompromised host as the main 'patho-mechanism', which is also supported by the observation that autologous HCT does not increase the risk of EBV-PTLD. 15 
EBV, MOLECULAR BASIS, INFECTION AND ROUTE TO MALIGNANCY
EBV is an enveloped and double-stranded DNA virus and member of the herpes virus family (HHV4). Approximately, 90% of adults have been infected with the virus by the age of 40 years. It usually infects human B cells via its interaction with gp350 (major envelope glycoprotein) and the target receptor CD21, a B-cell surface molecule homologous to the C3d complement receptor. After primary infection, the linear EBV genome becomes circular forming an episome often remaining latent in B cells. 16, 17 This has relevant implications for clinical approaches as antiviral agents such as ganciclovir inhibit the replication of linear EBV DNA but are ineffective against episomal DNA. In consequence, these drugs fail to prevent B-cell proliferation. 18 Therefore, these kind of antiviral agents have no place in the treatment of PTLD.
EBV-induced malignancy in vitro-lymphoblastoid cell lines EBV infection of resting B cells in vitro results in immortalized lymphoblastoid cell lines expressing the full repertoire of latent viral cycle proteins (six nuclear Ags: EBNA-1, EBNA-2, EBNA-3A, -3B, -3C, EBNA-LP, and three membrane proteins: LMP-1, LMP-2A, LMP-2B). This repertoire is also known as the latency III pattern. 19 In the latency period following primary EBV infection, these proteins are exposed to the immune system initiating a T-cell-based immune response later having a crucial role in immunosurveillance of the virus. Many of these cytotoxic T-cell responses target EBNA-3 protein 16 or LMP-2 protein 20 representing potential targets for cellular-based therapies. A key feature of EBV is its potency to induce malignancy in infected B cells. Extensive work has been done to identify and characterize the involved viral proteins. Here, LMP-1 acts as an oncogene providing proliferative signals via the nuclear factor kappa B pathway, 21 whereas BHFR1 blocks apoptosis by a BCL-2-like function. 22 EBV-induced malignancy in vivo-PTLD However, the in vivo transformation process is more a continuum than a single event. An uncontrolled EBV-driven B-cell proliferation leads to an extended half-life of virally infected cells and increases their likelihood of acquiring mutations resulting in a growth advantage and malignant transformation 19 ( Figure 1 ). As a consequence, PTLD shows a stage-dependent heterogeneous pattern changing the course of the disease. Here, the World Health Organization classification distinguishes four categories: (1) early lesions, (2) polymorphic PTLD, (3) monomorphic PTLD and (4) classical Hodgkin lymphoma-type PTLD. 23 In early lesions, a polyclonal lymphoid proliferation is found with B-, T-and plasma cells displaying no phenotypic aberrancy. In polymorphic PTLD, lymphoid cells show a more aggressive growth pattern characterized by destructive extranodal masses and the effacement of the underlying tissue architecture. In these lesions, monoclonal B cells were found, although these clones are less predominant than in monomorphic EBV-PTLD. 23, 24 In monomorphic EBV-PTLD, a monoclonal lymphoma has established displaying the morphological characteristics of diffuse large B-cell lymphoma including Burkitt's lymphoma often containing RAS, Myc and P53 mutations. Interestingly, some cells show an altered B-cell immunophenotype with low or minimal CD20 expression. 25, 26 It is reasonable that these cells may be less susceptible to anti-CD20 Abs such as rituximab giving the rationale for a pre-emptive therapy initiation in patients with early stages of EBV-PTLD.
CLINICAL AND LABORATORY PRESENTATION
In immunocompetent subjects, the primary infection with EBV often presents without visible symptoms. Probable symptoms like fever and lymphadenopathy are mainly attributed to the proliferation and activation of T cells in response to the infection. 16 This may be the reason why early EBV reactivation after HCT also causes only little or no symptoms. When finally symptomatic, patients are likely to present with fever and/or lymphadenopathy. When progressing further, organ involvement is possible often featuring severe hepatitis, pneumonia, colitis, nephritis and variable symptoms associated with central nervous system manifestation. 5, 27 In the laboratory, increasing levels of the lactate dehydrogenase regularly herald the clinical manifestation of PTLD. In cases of liver involvement, increased liver enzymes may be diagnosed as a surrogate of EBV hepatitis. Differential diagnosis also includes GVHD, haemolytic anaemia and other 28 Although rising EBV copy numbers are a broadly accepted warning for later PTLD development, the exact threshold is still subject of intense debate. Ahmad et al. 29 prospectively analysed a treatment schedule in 115 patients where a single RTq-PCR above 40 000 DNA genome copies per millilitre (gCop/mL) or two rising values above 10 000 gCop/mL served as criteria for immediate initiation of pre-emptive therapy with anti-CD20 Abs. In consequence, only a single patient developed EBV-PTLD who finally survived. Similar criteria were used by Omar et al. 10 who initiated a preemptive treatment with anti-CD20 Abs when RTq-PCR revealed 410 000 copies/mL or typical symptoms such as fever associated with lymphadenopathy suggestive of EBV-PTLD. Others prospectively evaluated a pre-emptive therapy for cord blood recipients. They chose a threshold of 1000 copies/mL to commence EBV therapy. 30 A comprehensive overview has been provided by Weinstock et al. 31 Varying standards of analysis and different units are associated with decreased inter-assay comparability and needs to be taken into consideration, as well. 9, 32 Taken together, pre-emptive screening of EBV load by RTq-PCR is certainly a valuable tool to monitor patients at risk. Nevertheless, the results require interpretation in the context of the patient's clinical presentation and other lab values finally making EBV-PTLD more or less likely. 33, 34 TREATMENT AND PROGNOSIS Therapeutic strategies in patients with evidence of active but asymptomatic EBV viraemia are considered to be of 'pre-emptive' nature while the treatment of overt EBV-PTLD is certainly intended 'therapeutically'. As an initial response to suspected or overt EBV-PTLD, the immunosuppression might be lowered or removed completely as long as the risk of consecutive GVHD development or progression can be disregarded. 9 In addition, the administration of anti-CD20 Abs represents a potent tool to unselectively destroy the viruses target cells finally limiting B-cell proliferation and reducing the risk of malignant transformation but also interfering with the immune reconstitution. 35 In the pre-emptive setting, the administration of the anti-CD20 Ab rituximab has been reported to be capable of preventing EBV-PTLD in roughly 90% of the cases. Applying rituximab in therapeutic intention, however, was associated with a reduced but still remarkable response rate of 63%. 9 Interestingly, rituximab was also effective in treating PTLD-like lesions in the central nervous system. 36 The optimal treatment schedule using rituximab is still debated and long-term side effects as a result of profound B-cell depletion are not fully understood.
Cellular therapies A more sophisticated and targeted approach for the treatment of EBV-PTLD is to selectively restore the impaired immune function by the adoptive transfer of EBV-specific cytotoxic T cells (CTLs). 37 There are different ways to generate EBV-specific CTLs. A basic approach uses EBV-infected lymphoblastic cell lines to sufficiently stimulate donor-derived T cells, expand them over a 3-to 4-week period and finally transfer them to the patient. In studies, these CTLs were capable of in vitro killing of EBV-infected targets and following the immune transfer to the patient further in vivo expansion of these CTLs was documented. 37, 38 Pre-emptive therapy using these CTLs resulted in a prevention of EBV-PTLD in 12 of 12 patients. In a long-term study, where 101 high-risk patients received EBV-specific CTLs in a prophylactic manner, no occurrence of EBV-PTLD was observed. However, when applied in the therapeutic setting, 11 of 13 patients achieved a sustained CR of their EBV-PTLD while 2 patients continued with uncontrolled EBV-PTLD. 37 Considering the dynamics of EBV-PTLD development, there is certainly a need for rapid availability of CTLs. Therefore, protocols have been developed to rapidly generate CTLs by overnight stimulation of donor mononuclear blood cells with EBVspecific peptides, selection of Ag-specific T cells by IFN-gamma surface capture assays and subsequent immunomagnetic selection. These CTLs were also effective in three of six patients with manifest EBV-PTLD. 39 Cellular therapies after haploidentical HCT or in cord blood recipients EBV-PTLD after haploidentical HCT was successfully treated using blood cells from the haploidentical donor as CTL source, expanded rapidly by a similar protocol. A CR was achieved in one exemplary case. 40 The occurrence of EBV-PTLD in recipients of allogeneic cord blood units represents a further challenge as the donor is usually not available. Therefore, alternative T-cell sources with at least a single match in one HLA-class I loci (for example, HLA-A201) are required. In this context, Barker et al. 41 reported on the successful use of third-party CTLs from a bank of 330 EBV-CTLs manufactured from healthy donors. This approach resulted in durable responses in two of two cord blood recipients with EBV-PTLD refractory to rituximab and taper of immunosuppression.
OUR INSTITUTIONAL APPROACH
At our institution, we have chosen to utilize a risk-adapted approach for the individual monitoring and subsequent therapy of EBV-PTLD based on our in-house experience and taking also international considerations into account. 28 This approach is summarized in Figure 2 .
We regard patients with anticipated prolonged impairment of T-cell immune reconstitution such as recipients of cord blood units or ex vivo CD34-selected or T-cell-depleted matched or mismatched (for example, haploidentical) hematopoietic cell grafts as high-risk patients for later PTLD development. Patients receiving Abs against T cells such as alemtuzumab and/or high doses of steroids for treatment of severe acute GVHD are also considered high risk. In contrast, the majority of our patients receiving T-cell-replete allografts with or without Abs for in vivo T-cell depletion to prevent GVHD are regarded standard risk. Highrisk patients will be monitored for EBV reactivation by weekly RTq-PCR until full immune reconstitution for CD4 þ and CD8 þ T cells has occurred and immunosuppressive agents have been tapered completely. Reactivation above 1000 copies/mL measured at least at two time points are treated immediately with rituximab (375 mg/m 2 weekly) until the viral load decreases below the threshold of detection. Standard-risk patients will be screened if EBV-PTLD is suspected clinically or based on laboratory results or imaging. When enlarged lymph nodes are present and easy to access, we favour biopsy or extirpation to histopathologically prove suspected EBV-PTLD. However, generally the transplant physician is confronted with a much more dubious situation where waiting for the final histopathological proof may be fatal. Therefore, we have defined a stage of suspected PTLD where we recommend immediate treatment with rituximab (375 mg/m 2 weekly). Simplified, we commence treatment when significant and rising EBV levels as measured by RTq-PCR and/or one or more of the following criteria occur: fever, lymphadenopathy, novel enlargement of spleen and liver, suspected extranodal manifestations, significantly increased and rising serum levels of lactate dehydrogenase and detection/increase of mono-or oligoclonal B-cell populations in the flow cytometry of the peripheral blood. However, it needs to be emphasized that our institutional approach is of suggestive nature, mainly thought to provide a guideline to the treating physician rather than a non-debatable rule.
Rituximab-refractory disease and lymphoma Patients with suspected or proven EBV-PTLD who are refractory to treatment with rituximab may be considered for alternative immunotherapeutic approaches such as the adoptive transfer of EBV-specific T cells, preferably in clinical trials. However, patients failing all therapeutic efforts and progressing to malignant lymphoma will require systemic chemotherapy following histopathological proof of disease. Here, the unique post transplant setting generally requires dose modifications and as a consequence of chemotherapy the donor-derived immune system may be stimulated, which may result in enhancement of graft-versusinfectious, graft-versus-lymphoma but also graft-versus-host effects.
CONCLUSIONS AND FURTHER OUTLOOK
The transfer of an allogeneic immune system into a host is generally associated with a timely limited impairment of the recipient's immune function afterward. This is mainly due to profound ex vivo or in vivo T-cell depletion or the administration of potent immunosuppressive agents after transplantation. Opportunistic viruses such as the human herpes virus family member EBV are frequently making advantage of this environment and may induce B-cell proliferation finally leading to EBV-PTLD and malignant lymphoma. The exact incidence of EBV-induced PTLD remains unknown and likely differs in certain sub-populations of patients. Here the individual degree of the host's immunodeficiency appears to represent an important risk factor for EBV-PTLD development. Particularly, T-cell-depleted allogeneic HCT in the mismatched (haploidentical) setting, cord blood transplantation and severe immunosuppression using T-cell Abs and/or steroids for GVHD treatment are associated with an increased risk for EBV-PTLD development. 42, 43 Although the taper of immunosuppression and chemotherapy has long been the only therapeutic choice, nowadays the use of anti-CD20 Ab rituximab offers a further, highly potent treatment option. The true challenge of the present appears to be the optimization of the timing of rituximab administration. Particularly in high-risk scenarios where fast track progression from EBV-reactivation to EBV-PTLD and malignant lymphoma can be awaited, a delay of treatment should be avoided. Therefore, we emphasize the need for regular screening processes and subsequent pre-emptive therapy particularly in patients at high risk for developing EBV-PTLD. In the standard-risk scenario, further factors such as clinical symptoms and/or laboratory finding in addition to qt-PCR-based measurement of the EBV load need to be taken into account leaving the physician often with a difficult decision when to commence treatment. It needs to be emphasized that there is no exact statistically validated definition of a high-risk group for PTLD development. Therefore, the transplant physician needs to be aware of the fact that EBV-PTLD can principally occur after allogeneic HCT sooner or later. The sufficient reconstitution of the donor-derived immune system in the absence of immunosuppression appears to provide a reasonable degree of protection from PTLD-EBV. 44 For those patients failing to respond to rituximab, novel T-cellbased cellular therapies still offer the chance of cure without chemotherapy. Here, today's challenges are to make an at least partially HLA-compatible, highly purified T-cell product available in a timely manner for every patient in need. 
